News
-
-
REGULATED PRESS RELEASE
BIOFIRE® FILMARRAY® Tropical Fever Panel, a syndromic PCR test targeting causes of tropical fever infections, receives U.S. FDA Special 510(k) clearance
bioMérieux receives U.S. FDA Special 510(k) clearance for BIOFIRE® FILMARRAY® Tropical Fever Panel, an innovative PCR test identifying tropical fever pathogens for optimized treatment -
-
-
-
REGULATED PRESS RELEASE
bioMérieux – Third-Quarter 2024 Business Review
bioMérieux reports strong +10.3% organic sales growth, reaching €2,871m in the first nine months of 2024, driven by growth drivers like GO•28 strategic plan and BIOFIRE® respiratory panels. Q3 2024 shows an +11% organic sales growth with confirmation of 2024 full-year revised guidance. CEO Pierre Boulud expresses confidence in achieving targets -
-
REGULATED PRESS RELEASE
bioMérieux receives CE-marking for VIDAS® VITAMIN B12 TOTAL, a blood test to measure total Vitamin B12 concentration
bioMerieux announces CE-marking for VIDAS Vitamin B12 Total, an automated blood test to measure total B12 concentration in serum or plasma, aiding in the assessment of B12 status and optimizing patient care -
-
REGULATED PRESS RELEASE
bioMérieux – First-Half 2024 Results
